UroGen Pharma Ltd. (URGN)
NASDAQ: URGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
URGN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.36B
- Forward P/E
- 11.08
- EPS (TTM)
- -$1.31
- Dividend yield
- None
- 52-week range
- 16.50 – 50.81
- Day range
- 27.58 – 31.90
- Volume / Avg
- 2.40M / 1.11M
- Beta
- —
- Shares outstanding
- 49.05M
52-week range
URGN stock today
Shares of UroGen Pharma (URGN) finished lower on Nov 20 at $27.65, a drop of 12.86% or $4.08 per share, versus the S&P 500's 3.70% decline. Volume was 2.2x the average at 2.40M shares, a sign of unusually heavy trading. At this level, URGN sits in the middle of its 52-week range of $16.50 to $50.81: 45.6% below the high, set on Aug 19, 2026 and 67.6% above the low.
URGN is up 18.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 6.9%. UroGen Pharma has posted a net loss over the last twelve months (EPS of -$1.31), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About UroGen Pharma
Company profileUroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Elizabeth A. Barrett
- Headquarters
- Princeton, NJ
- Employees
- 300
- IPO year
- 2017
- Website
- urogen.com
Financial highlights
Full financialsIn fiscal 2025, UroGen Pharma generated $109.8 million in revenue, up 21.4% from fiscal 2024, its 6th consecutive year of revenue growth. UroGen Pharma reported a net loss of $153.5 million, compared with a loss of $126.9 million a year earlier. Gross margin was 88.7% (down from 90.2%) and operating margin -113.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $109.79M | $90.40M | $82.71M | $64.36M | $48.04M |
| Growth | +21.45% | +9.29% | +28.52% | +33.96% | +307.17% |
| Net income | $-153.49M | $-126.87M | $-102.24M | $-109.78M | $-110.82M |
| EPS (diluted) | — | — | — | — | $-4.96 |
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$60.71+119.57%
- Strong buy 1
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.03 vs $0.05
- Surprise
- -160.00%
URGN news
All URGN news- The Gel That Became a BusinessNasdaqURGN, LEN.B
- Why is UroGen Pharma stock sliding today?Investing.com
- UroGen (URGN) Q3 2026 Earnings Call TranscriptNasdaq
- UroGen Pharma Ltd. Reports Third Quarter 2026 Financial Results and FDA Acceptance of UGN-103 NDANasdaq
- UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and HighlightsGlobeNewswire
- UroGen Pharma Q3 2026 Earnings PreviewSeeking Alpha
- UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder CancerGlobeNewswire
- UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial CancerGlobeNewswire
UroGen Pharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| QUREuniQure N.V. | 19.35 | -4.35% | $1.36B | vs URGN |
| PAHCPhibro Animal Health Corporation Class A | 33.29 | -2.32% | $1.35B | vs URGN |
| NBTXNanobiotix S.A. ADR | 26.50 | -2.98% | $1.35B | vs URGN |
| NUVBNuvation Bio Inc. Class A | 3.80 | -0.26% | $1.34B | vs URGN |
| RAPPRapport Therapeutics Inc. | 23.16 | -1.82% | $1.37B | vs URGN |
| ANABAnaptysBio Inc. | 46.63 | -1.62% | $1.39B | vs URGN |
| TYRATyra Biosciences Inc. | 20.12 | +1.98% | $1.39B | vs URGN |
| NRIXNurix Therapeutics Inc. | 12.85 | -5.55% | $1.40B | vs URGN |
Indexes, lists and sector
UroGen Pharma stock FAQ
What is UroGen Pharma's stock price today?
URGN last traded at $27.65 as of Nov 20, 4:00 PM EST, down 12.86% on the day. Prices are delayed at least 15 minutes.
Who is UroGen Pharma's CEO?
Ms. Elizabeth A. Barrett is the chief executive officer of UroGen Pharma Ltd., which has about 300 employees.
What is the URGN 52-week high?
The 52-week high for URGN is $50.81 and the 52-week low is $16.50. The stock is currently 45.6% below its high.